Tokyo, Japan, May 13, 2013 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will cancel its treasury stock, pursuant to Article 178 of the Japanese Corporate Law.
1. Class of shares to be cancelled : Common stock of the Company
2. Number of shares to be cancelled: 11 million shares
(Representing 2.4% of issued shares prior to cancellation)
3. Cancellation date: May 31, 2013
Following cancellation, the Company will have 456,964,635 issued shares.
Total number of the Company’s treasury stock after cancellation will be 5,788,579.
(Expected numbers of shares described above 1 and 2 were calculated on the basis of the issued shares and the Company’s treasury stock as of March 31, 2013, respectively.)